Clinical Research Directory
Browse clinical research sites, groups, and studies.
Ertugliflozin: Cardioprotective Effects on Epicardial Fat
Sponsor: Stanford University
Summary
The purpose of this study is to learn if Sodium-Glucose Cotransporter 2 inhibitor (SGLT2i) medications enhance beneficial properties of epicardial adipose tissue including metabolic flexibility, insulin sensitivity, decreased cell size and reduced inflammation.
Key Details
Gender
All
Age Range
18 Years - 80 Years
Study Type
INTERVENTIONAL
Enrollment
61
Start Date
2020-07-01
Completion Date
2023-12-31
Last Updated
2026-06-04
Healthy Volunteers
No
Interventions
Ertugliflozin
Adipose tissue samples collected from participants were treated with Ertugliflozin at a concentration of 25 µM in vitro. This treatment was applied in a laboratory setting to assess the effects of Ertugliflozin on lipolysis, inflammatory cytokine release, and gene expression in epicardial, pericardial, and subcutaneous adipose tissue
Locations (1)
Stanford University
Stanford, California, United States